Krilogy Financial’s Karyopharm Therapeutics KPTI Stock Holding History

Krilogy Financial’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-13	Closed	-$2K	–	757
2017 Q1	$2K	Hold	13	–	–	﹤0.01%	651
2016 Q4	$2K	Hold	13	–	–	﹤0.01%	651
2016 Q3	$2K	Hold	13	–	–	﹤0.01%	664
2016 Q2	$1K	Hold	13	–	–	﹤0.01%	715
2016 Q1	$2K	Hold	13	–	–	﹤0.01%	607
2015 Q4	$3K	Hold	13	–	–	﹤0.01%	354
2015 Q3	$2K	Buy	+13	New	+$3.48K	﹤0.01%	549

Other funds holding KPTI

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return

Krilogy Financial's KPTI Position: Q2 2017 in Review

Krilogy Financial sold out of Karyopharm Therapeutics (KPTI) in Q2 2017, closing a stake of 13 shares — an estimated $2K sold.

Krilogy Financial first reported a position in KPTI in Q3 2015 and held it in 7 quarters. The position peaked at $3K in Q4 2015. 73 funds tracked by Wall St. Rank hold KPTI as of Q2 2017.

Krilogy Financial reported no remaining Karyopharm Therapeutics position as of Q2 2017 after selling out during the quarter.
Krilogy Financial sold 13 Karyopharm Therapeutics shares in Q2 2017, an estimated $2K.
Krilogy Financial first reported a position in Karyopharm Therapeutics in Q3 2015 and held it in 7 quarters.
Krilogy Financial's Karyopharm Therapeutics position peaked at $3K in Q4 2015.
73 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2017.

Based on Krilogy Financial's 13F filing for Q2 2017, filed 15 Aug 2017.